HIGHLIGHTS
- who: Bettina Gerner and colleagues from the Institute for Pharmacy and Food Chemistry, University of Wu00fcrzburg, Wu00fcrzburg, Germany have published the Article: A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus HostDisease Patients, in the Journal: Pharmaceutics 2022, 14, 2556. of 24/Oct/2022
- what: Knowledge of RUX exposure under concomitant POS treatment is scarce and recommendations on dose modifications are inconsistent. pharmacokinetic (PBPK) model was developed to investigate the drug-drug interaction (DDI) between POS and RUX. As no investigations have been . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.